29 results
6-K
EX-99.1
IMCR
Immunocore Holdings plc
7 Dec 21
Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:10pm
, in selected advanced solid tumors.
IMC-C103C was developed using the company’s innovative ImmTAC® technology platform and is being developed
6-K
EX-99.1
IMCR
Immunocore Holdings plc
24 Aug 21
Current report (foreign)
4:33pm
; and Promising Innovative Medicine (PIM) designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma. Tebentafusp has also been
6-K
EX-99.1
IMCR
Immunocore Holdings plc
6 Jun 22
Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic
4:21pm
Innovative Medicine (PIM) designation under the UK Early Access to Medicines Scheme for mUM. In January and April 2022, the FDA and the European Commission
6-K
EX-99.1
IMCR
Immunocore Holdings plc
2 Dec 22
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
5:08pm
of diseases, including cancer, autoimmune and infectious diseases, and Gadeta B.V., an innovative clinical-stage biopharmaceutical company pioneering
6-K
EX-99.1
IMCR
Immunocore Holdings plc
3 Jun 22
Sanofi will evaluate KIMMTRAK in combination with SAR444245 as part of its ongoing Phase 1 study in advanced unresectable or metastatic skin cancers
4:05pm
Assessment by the EMA, and Promising Innovative Medicine (PIM) designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma
6-K
EX-99.1
2bgc9unoptaq
4 Apr 22
European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
4:06pm
6-K
EX-99.1
w90yq5uvdybouw0b
26 Jan 22
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
4:29pm
6-K
EX-99.3
172v7 xzdtiuq
11 Aug 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
6-K
EX-99.3
4ubbpc4hj z2mh2
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
6-K
EX-99.3
77u342c
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
EX-99.1
4ij06rsudn13x 7e5
3 Mar 22
Immunocore Reports Full Year 2021 Financial Results
7:01am
6-K
EX-99.3
edj c72s1mao9xtc2q
7 Nov 23
Current report (foreign)
7:09am
8-K
EX-99.1
0hs63unw0l4
8 May 24
Immunocore reports first quarter financial results and provides a business update
7:13am
6-K
EX-99.3
l1qc3ez
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.2
1zcz6jw34inqkzn1 2o
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.2
nx1 7u0p54ce
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
10-K
9u79xlcd1vea jbdhx4q
28 Feb 24
Annual report
7:33am
DRS
wh2vingg
17 Nov 20
Draft registration statement
12:00am
DRS/A
2e9negyz
19 Nov 20
Draft registration statement (amended)
12:00am
F-1
EX-10.7
bqacv7i
15 Jan 21
Registration statement (foreign)
4:57pm